124 related articles for article (PubMed ID: 29498921)
1. ENHANCED BETA-CATENIN EXPRESSION IS ASSOCIATED WITH RECURRENCE OF PAPILLARY THYROID CARCINOMA.
Kordestani Z; Sanjari M; Safavi M; Mashrouteh M; Asadikaram G; Abadi MFS; Mirzazadeh A
Endocr Pract; 2018 May; 24(5):411-418. PubMed ID: 29498921
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of Cyclin D1 and C-myc, a prognostic factor and possible mechanism for recurrence of papillary thyroid carcinoma.
Sanjari M; Kordestani Z; Safavi M; Mashrouteh M; FekriSoofiAbadi M; Ghaseminejad Tafreshi A
Sci Rep; 2020 Mar; 10(1):5100. PubMed ID: 32198408
[TBL] [Abstract][Full Text] [Related]
3. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
4. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
5. Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases.
Lin JD; Liou MJ; Chao TC; Weng HF; Ho YS
Endocr Relat Cancer; 1999 Mar; 6(1):109-15. PubMed ID: 10732793
[TBL] [Abstract][Full Text] [Related]
6. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma.
Luo D; Chen H; Lu P; Li X; Long M; Peng X; Huang M; Huang K; Lin S; Tan L; Zhu Y; Chen Z; Ouyang N; Li H
Cancer Biomark; 2017; 18(3):273-284. PubMed ID: 28009325
[TBL] [Abstract][Full Text] [Related]
7. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
8. Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.
Fehér LZ; Pocsay G; Krenács L; Zvara A; Bagdi E; Pocsay R; Lukács G; Győry F; Gazdag A; Tarkó E; Puskás LG
Pathol Oncol Res; 2012 Apr; 18(2):449-58. PubMed ID: 22161024
[TBL] [Abstract][Full Text] [Related]
9. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
10. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.
He J; Tian Z; Yao X; Yao B; Liu Y; Yang J
Clin Exp Metastasis; 2020 Apr; 37(2):257-267. PubMed ID: 31792675
[TBL] [Abstract][Full Text] [Related]
11. Association of tumor size and focality with recurrence/persistence in papillary thyroid cancer patients treated with total thyroidectomy along with radioactive-iodine ablation and TSH suppression.
Khan M; Syed AA; Khan AI; Hussain SR; Urooj N
Updates Surg; 2018 Mar; 70(1):121-127. PubMed ID: 28550398
[TBL] [Abstract][Full Text] [Related]
12. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
Zhou C; Duan D; Liu S
Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
[TBL] [Abstract][Full Text] [Related]
13. Integrated bioinformatics analysis reveals that the expression of cathepsin S is associated with lymph node metastasis and poor prognosis in papillary thyroid cancer.
Tan J; Qian X; Song B; An X; Cai T; Zuo Z; Ding D; Lu Y; Li H
Oncol Rep; 2018 Jul; 40(1):111-122. PubMed ID: 29749483
[TBL] [Abstract][Full Text] [Related]
14. Expression of MAGE A1-6 and the clinical characteristics of papillary thyroid carcinoma.
Lee HS; Kim SW; Hong JC; Jung SB; Jeon CH; Park JW; Park SY; Lee KD
Anticancer Res; 2013 Apr; 33(4):1731-5. PubMed ID: 23564824
[TBL] [Abstract][Full Text] [Related]
15. Survival Analysis of Papillary Thyroid Carcinoma in Relation to Stage and Recurrence Risk: A 20-Year Experience in Pakistan.
Hassan A; Razi M; Riaz S; Khalid M; Nawaz MK; Syed AA; Bashir H
Clin Nucl Med; 2016 Aug; 41(8):606-13. PubMed ID: 27124680
[TBL] [Abstract][Full Text] [Related]
16. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
17. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
18. BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.
Zoghlami A; Roussel F; Sabourin JC; Kuhn JM; Marie JP; Dehesdin D; Choussy O
Eur Ann Otorhinolaryngol Head Neck Dis; 2014 Feb; 131(1):7-13. PubMed ID: 23845288
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
20. MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.
Sondermann A; Andreghetto FM; Moulatlet AC; da Silva Victor E; de Castro MG; Nunes FD; Brandão LG; Severino P
Clin Exp Metastasis; 2015 Aug; 32(6):521-30. PubMed ID: 26007293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
